Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Liabilities and Shareholders Equity (2018 - 2019)

DiaMedica Therapeutics' Liabilities and Shareholders Equity history spans 2 years, with the latest figure at $11.0 million for Q3 2019.

  • For Q3 2019, Liabilities and Shareholders Equity changed N/A year-over-year to $11.0 million; the TTM value through Dec 2019 reached $39.3 million, up 114.46%, while the annual FY2018 figure was $18.3 million, N/A changed from the prior year.
  • Liabilities and Shareholders Equity reached $11.0 million in Q3 2019 per DMAC's latest filing, down from $12.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $18.3 million in Q4 2018 to a low of $11.0 million in Q3 2019.